Skip to content

Development and Effect Evaluation of a Management Protocol for High-Risk Patients with Hereditary Ovarian Cancer Based on the Ottawa Model of Research Use

Development and Effect Evaluation of a Management Protocol for High-Risk Patients with Hereditary Ovarian Cancer Based on the Ottawa Model of Research Use

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117543
Enrollment
Unknown
Registered
2026-01-26
Start date
2026-01-26
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hereditary ovarian cancer

Interventions

intervention group:OMRU-Based Management Protocol for High-Risk Patients with Hereditary Ovarian Cancer
control group:routine intervention
Interview Team:N/A

Sponsors

Zhejiang Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.High-risk patients with ovarian cancer; 2.Aged 18–60 years; 3.With an anticipated survival time of =24 months; 4.Capable of independently completing questionnaires, communicating effectively, and cooperating with follow-up procedures; 5.Without definite risk of loss to follow-up (e.g., no plan for long-term residence in other areas, no severe underlying diseases that would preclude follow-up participation); 6.Having received medical treatment or health screening at our hospital and signed the informed consent form;

Exclusion criteria

Exclusion criteria: 1.Patients with a confirmed diagnosis of ovarian cancer (including carcinoma in situ and invasive carcinoma) or other malignant tumors, who are undergoing radiotherapy, chemotherapy, targeted therapy, or immunotherapy; 2.Those with severe organ failure involving the heart, liver, kidneys, lungs, or other vital organs, or in the acute exacerbation stage of severe chronic diseases, and thus unable to tolerate the intervention measures; 3.Those with a history of mental illness, cognitive impairment, or language communication disorders; women who are pregnant or lactating.

Design outcomes

Primary

MeasureTime frame
Genetic testing compliance rate;Regular screening completion rate;;Genetic counseling participation rate;First-degree relative screening rate;Preventive surgery implementation rate;

Secondary

MeasureTime frame
anxiety and depression levels;self-efficacy;

Countries

China

Contacts

Public ContactFan Tingting

Zhejiang Cancer Hospital

835533379@qq.com+86 575 8812 8121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026